News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

July 27, 2015

GSK Malaria Candidate Vaccine First to be Recommended by European Regulators

July 27, 2015.

EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for GSK's malaria candidate vaccine Mosquirix, also known as RTS,S, in children aged 6 weeks to 17 months.    RTS,S was developed in partnership with the PATH Malaria Vaccine Initiative (MVI) and is the first candidate vaccine for the prevention of malaria to reach this milestone. While other vaccines tackle viruses or bacteria, RTS,S has been designed to prevent malaria caused by the Plasmodium falciparum parasite, which is most prevalent in sub-Saharan Africa (SSA). In 2013, there were an estimated 584,000 deaths from malaria with around 90% of these occurring in SSA, and 83% in children under the age of five in SSA.   GSK has committed to a not-for-profit price for RTS,S. If approved, the price of RTS,S would cover the cost of manufacturing the vaccine together with a small return of around five per cent that will be reinvested in research and development for second-generation malaria vaccines, or vaccines against other neglected tropical diseases.   Two of the WHO’s independent advisory groups, the Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Committee (MPAC) will now jointly review the evidence base for RTS,S and make a joint policy recommendation for how it might be used alongside other tools to prevent malaria in the event the vaccine candidate is approved by national regulatory authorities in SSA. The WHO has indicated that such a policy recommendation may be possible by end of this year.  

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser
Related Content
Advertisement
Gaugarin Oliver
August 3rd 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 3rd 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Stock.adobe.com
August 3rd 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Snyder and Capan
August 3rd 2025

Accelerating AI: Q&A with Faruk Capan and Scott Snyder

Pharmaceutical Executive
The EVERSANA team discusses its new technology center that has a goal of pharmatizing AI.
Stock.adobe.com
August 3rd 2025

TrueMed and Alliance Pharmaceuticals Ltd Form Partnership to Create AI-Powered Counterfeit Solutions

Nicholas Jacobus
Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.
Kevin Riley
August 3rd 2025

AI Can’t Lead. Healthcare Needs Leaders

Kevin Riley
It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.
Related Content
Advertisement
Gaugarin Oliver
August 3rd 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 3rd 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Stock.adobe.com
August 3rd 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Snyder and Capan
August 3rd 2025

Accelerating AI: Q&A with Faruk Capan and Scott Snyder

Pharmaceutical Executive
The EVERSANA team discusses its new technology center that has a goal of pharmatizing AI.
Stock.adobe.com
August 3rd 2025

TrueMed and Alliance Pharmaceuticals Ltd Form Partnership to Create AI-Powered Counterfeit Solutions

Nicholas Jacobus
Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.
Kevin Riley
August 3rd 2025

AI Can’t Lead. Healthcare Needs Leaders

Kevin Riley
It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.